ReviewBritish journal of pharmacology2015
The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs.
Review in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- MicroRNA-206 as a Novel Potential Prognostic Biomarker for Distinguishing Philadelphia Chromosome-Positive and Negative ALL Patients.International journal of hematology-oncology and stem cell research · 2026Article
- Circulating miRNA as diagnostic tools for gynecological diseases and their applications in biosensor development.Analytical and bioanalytical chemistry · 2026Review
- Pharmacoepigenomics in Personalized Medicine: A Hypothesis-Generating Approach to Introduce CpG-PGx SNPs as New Candidates for a Systematic Insight into Genomic-Epigenomic-Phenomic-Pharmacogenomics (G-E-Ph-PGx) Axis.Journal of personalized medicine · 2025Article
- Impact of steroid therapy on pediatric acute liver failure: prognostic implication and interplay between TNF-α and miR-122.Molecular and cellular pediatrics · 2024Article
- Promises and challenges in pharmacoepigenetics.Cambridge prisms. Precision medicine · 2023Review
- Understanding Pharmaco-Epigenomic Response of Antipsychotic Drugs Using Genome-Wide MicroRNA Expression Profile in Liver Cell Line.Frontiers in molecular neuroscience · 2022Article
- Fundamental dietary specialisation explains differential use of resources within a koala population.Oecologia · 2021Article
- Profiling 25 Bone Marrow microRNAs in Acute Leukemias and Secondary Nonleukemic Hematopoietic Conditions.Biomedicines · 2020Article
- Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs' World.Cells · 2019Review
- Germline variants in cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- miR-34 modulates apoptotic gene expression in Ingenol mebutate treated keloid fibroblasts.Molecular medicine reports · 2018Article
- Overview of microRNA Modulation in Analgesic Research.Current protocols in pharmacology · 2017Review
- The Promises of Quantitative Proteomics in Precision Medicine.Journal of pharmaceutical sciences · 2017Article
- MiRNAs and miRNA Polymorphisms Modify Drug Response.International journal of environmental research and public health · 2016Review
- Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells.Biochemical pharmacology · 2015Article
- Epigenetics and pharmacology.British journal of pharmacology · 2015Article
- microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.Biomarkers in medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
The importance of genetic factors (e.g. sequence variation) in the absorption, distribution, metabolism, excretion (ADME) and overall efficacy of therapeutic agents is well established. Our ability to identify, interpret and utilize these factors is the subject of much clinical investigation and therapeutic development. However, drug ADME and efficacy are also heavily influenced by epigenetic factors such as DNA/histone methylation and non-coding RNAs [especially microRNAs (miRNAs)]. Results from studies using tools, such as in silico miRNA target prediction, in vitro functional assays, nucleic acid profiling/sequencing and high-throughput proteomics, are rapidly expanding our knowledge of these factors and their effects on drug metabolism. Although these studies reveal a complex regulation of drug ADME, an increased understanding of the molecular interplay between the genome, epigenome and transcriptome has the potential to provide practically useful strategies to facilitate drug development, optimize therapeutic efficacy, circumvent adverse effects, yield novel diagnostics and ultimately become an integral component of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.